Signe Ledou Nielsen

Medicine & Life Sciences

1. B-Cell Lymphoma 100%
2. Lymphoma, Large B-Cell, Diffuse 69%
3. Neoplasms 43%
4. Lymphoma 39%
5. Hypoglycemia 31%
6. R-CHOP protocol 31%
7. Drug Therapy 27%
8. Linear IgA Bullous Dermatosis 27%
9. Survival 26%
10. Urinary Bladder 26%
11. Gene Dosage 26%
12. B-Lymphocytes 26%
13. Mycobacterium marinum 25%
14. Adrenergic Receptors 25%
15. Biomarkers 25%
16. Burkitt Lymphoma 23%
17. Topoisomerase I Inhibitors 23%
18. Omalizumab 23%
19. Rituximab 23%
20. Tick-Borne Diseases 23%
21. Chenodeoxycholic Acid 23%
22. Xenon 22%
23. Etoposide 21%
24. Plasmacytoma 20%
25. Glucagon 20%
26. Plasma Volume 19%
27. Irinotecan 19%
28. Glucagon-Like Peptide 1 19%
29. Gastric Bypass 18%
30. Hematocrit 18%
31. Basal Cell Carcinoma 18%
32. Opportunistic Infections 18%
33. Bile Acids and Salts 17%
34. Fluorescence In Situ Hybridization 16%
35. Microspheres 16%
36. Human Herpesvirus 4 16%
37. Vascular Resistance 15%
38. Therapeutics 15%
39. Non-Hodgkin's Lymphoma 15%
40. Infection with Mycobacterium marinum 13%
41. Glucose 13%
42. Genes 13%
43. Vaccination 13%
44. Colorectal Neoplasms 13%
45. Swine 13%
46. Tumor Lysis Syndrome 12%
47. Vaccines 12%
48. Learning 12%
49. Biopsy 11%
50. Proto-Oncogene Proteins c-bcl-2 11%